Literature DB >> 29451690

Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor.

S Nasifoglu1, B Heinrich2, J Welzel1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29451690     DOI: 10.1111/bjd.16468

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  6 in total

1.  Dealing with Corticosteroid and High-Dose Cyclosporine Therapy in a Pyoderma Gangrenosum Patient Contracting a COVID-19 Infection.

Authors:  Marcella Ricardis May; Albert Rübben; Andrea Lennertz; Luk Vanstreels; Marike Leijs
Journal:  J Pers Med       Date:  2022-01-27

Review 2.  Emerging Topical and Systemic JAK Inhibitors in Dermatology.

Authors:  Farzan Solimani; Katharina Meier; Kamran Ghoreschi
Journal:  Front Immunol       Date:  2019-12-03       Impact factor: 7.561

Review 3.  Skin manifestations in spondyloarthritis.

Authors:  Katharina Meier; Alexandra Schloegl; Denis Poddubnyy; Kamran Ghoreschi
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-12-08       Impact factor: 5.346

4.  Pyoderma Gangrenosum, Acne, and Hidradenitis Suppurativa Syndrome: A Case Report and Literature Review.

Authors:  Jundong Huang; Lemuel Shui-Lun Tsang; Wei Shi; Ji Li
Journal:  Front Med (Lausanne)       Date:  2022-03-24

Review 5.  Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments.

Authors:  Carlo Alberto Maronese; Matthew A Pimentel; May M Li; Alex G Ortega-Loayza; Angelo Valerio Marzano; Giovanni Genovese
Journal:  Am J Clin Dermatol       Date:  2022-05-24       Impact factor: 6.233

Review 6.  Recent advances in managing and understanding pyoderma gangrenosum.

Authors:  Josh Fletcher; Raed Alhusayen; Afsaneh Alavi
Journal:  F1000Res       Date:  2019-12-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.